Glaxo considering options for Lucozade and Ribena brands

GlaxoSmithKline has put iconic drinks Lucozade and Ribena under review as it looks for the “best ways to ensure their continued growth”.

The drugs giant will consider all strategic options for the brands, which are primarily sold in western markets. It did not disclose the options under review, but it is likely they will include new ownership for the brands.